Integrated Isogenic Human Induced Pluripotent Stem Cell–Based Liver and Heart Microphysiological Systems Predict Unsafe Drug–Drug Interaction
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Three-dimensional (3D) microphysiological systems (MPSs) mimicking human organ function in vitro are an emerging alternative to conventional monolayer cell culture and animal models for drug development. Human induced pluripotent stem cells (hiPSCs) have the potential to capture the diversity of human genetics and provide an unlimited supply of cells. Combining hiPSCs with microfluidics technology in MPSs offers new perspectives for drug development. Here, the integration of a newly developed liver MPS with a cardiac MPS—both created with the same hiPSC line—to study drug–drug interaction (DDI) is reported. As a prominent example of clinically relevant DDI, the interaction of the arrhythmogenic gastroprokinetic cisapride with the fungicide ketoconazole was investigated. As seen in patients, metabolic conversion of cisapride to non-arrhythmogenic norcisapride in the liver MPS by the cytochrome P450 enzyme CYP3A4 was inhibited by ketoconazole, leading to arrhythmia in the cardiac MPS. These results establish integration of hiPSC-based liver and cardiac MPSs to facilitate screening for DDI, and thus drug efficacy and toxicity, isogenic in the same genetic background.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 2×
“5 billion USD (Herper, 2013; DiMasi et al., 2016) and can take ∼10–15 years (Mathur et al.”
InfluentialMembrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“Additionally, animal studies can only partially recapitulate patient-specific factors such as genetics, age, environment, and concomitant diseases (Olson et al., 2000).”
Liver regeneration: from myth to mechanism
Taub, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1489 · Cited by 1,567 · cited 1×
“…models to predict DILI has led to the development of in vitro liver models; however, current versions have limitations, most notably due to the complexity of the liver, which performs more than 500 functions, including metabolic, synthetic, immunologic, and detoxification processes (Taub, 2004).”
Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280 · cited 1×
“The second is for testing of more challenging hepatotoxicity mechanisms and complex disease models over longer time periods with high content models representing physiologically relevant fluid flow and cell types (Hewitt et al., 2007; Song et al., 2009; Godoy et al., 2013; Soldatow et al., 2013).”
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 1×
“More physiological medium-to-cell ratios can be achieved by using the small system volumes of microfluidic devices (Khetani and Bhatia, 2008; Dash et al., 2009), which preserves the efficacy of low-concentration autocrine and paracrine signals, including secreted molecules, growth factors, matrices, and hormones (Abhy…”
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices
Halldorsson, S., Lucumi, E., Gómez-Sjöberg, R., & Fleming, R. M. T. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.07.029 · Cited by 1,027 · cited 1×
“While PDMS is widely used to build microfluidic devices, due to its biocompatibility and convenience for microfabrication, the material has the disadvantage that it can absorb small molecules with low LogP values (van Meer et al., 2017; Halldorsson et al., 2015).”
Bhatia, S. N., Balis, U. J., Yarmush, M. L., & Toner, M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1883 · Cited by 890 · cited 1×
“Whether a small subset of hiPSCs not committing to hepatocyte differentiation, but giving rise to mesenchymal cell types instead (data not shown), further aided hiPSC-Hep function remains to be determined (Bhatia et al., 1999).”
Research works printed but not linked: 98
- Abboud, 2007, Drug-Induced Liver Injury, Drug Saf., 30, 277, 10.2165/00002018-200730040-00001 · DOI · Paper page
- Abhyankar, 2006, Characterization of a Membrane-Based Gradient Generator for Use in Cell-Signaling Studies, Lab. Chip, 6, 389, 10.1039/b514133h · DOI · Paper page
- Albert, 2007, Rat Liver Sinusoidal Endothelial Cells Survive without Exogenous VEGF in 3D Perfused Co-cultures with Hepatocytes, FASEB J., 21, 2564, 10.1096/fj.06-7473com · DOI · Paper page
- Allen, 2003, Formation of Steady-State Oxygen Gradients In Vitro: Application to Liver Zonation, Biotechnol. Bioeng., 82, 253, 10.1002/bit.10569 · DOI · Paper page
- Ardalani, 2019, 3-D Culture and Endothelial Cells Improve Maturity of Human Pluripotent Stem Cell-Derived Hepatocytes, Acta Biomater., 95, 371, 10.1016/j.actbio.2019.07.047 · DOI · Paper page
- Bacabac, 2005, Dynamic Shear Stress in Parallel-Plate Flow Chambers, J. Biomech., 38, 159, 10.1016/j.jbiomech.2004.03.020 · DOI · Paper page
- Baert, 2020, A Multi-Organ-Chip Co-culture of Liver and Testis Equivalents: a First Step toward a Systemic Male Reprotoxicity Model, Hum. Reprod., 35, 1029, 10.1093/humrep/deaa057 · DOI
- Bale, 2014, In Vitroplatforms for Evaluating Liver Toxicity, Exp. Biol. Med. (Maywood), 239, 1180, 10.1177/1535370214531872 · DOI · Paper page
- Berger, 2014, Enhancing the Functional Maturity of iPSC-Derived Human Hepatocytes via Controlled Presentation of Cell-Cell Interactions In Vitro, Hepatology, 61, 1370, 10.1002/hep.27621 · DOI · Paper page
- Bhushan, 2016, New Technologies in Drug Metabolism and Toxicity Screening: Organ-To-Organ Interaction, Expert Opin. Drug Metab. Toxicol., 12, 475, 10.1517/17425255.2016.1162292 · DOI
- Bircsak, 2021, A 3D Microfluidic Liver Model for High Throughput Compound Toxicity Screening in the OrganoPlate, Toxicology, 450, 152667, 10.1016/j.tox.2020.152667 · DOI · Paper page
- Boeri, 2019, Advanced Organ-On-A-Chip Devices to Investigate Liver Multi-Organ Communication: Focus on Gut, Microbiota Brain Bioeng. (Basel), 6, 10.3390/bioengineering6040091 · DOI
- Boggess, 2019, New Molecular Scaffolds for Fluorescent Voltage Indicators, ACS Chem. Biol., 14, 390, 10.1021/acschembio.8b00978 · DOI
- Bohets, 2000, Identification of the Cytochrome P450 Enzymes Involved in the Metabolism of Cisapride: In Vitro Studies of Potential Co-medication Interactions, Br. J. Pharmacol., 129, 1655, 10.1038/sj.bjp.0703246 · DOI
- Braet, 2002, Structural and Functional Aspects of Liver Sinusoidal Endothelial Cell Fenestrae: a Review, Comp. Hepatol., 1, 1, 10.1186/1476-5926-1-1 · DOI · Paper page
- Chakraborty, 2007, Multiscale Model for Pulmonary Oxygen Uptake and its Application to Quantify Hypoxemia in Hepatopulmonary Syndrome, J. Theor. Biol., 244, 190, 10.1016/j.jtbi.2006.07.030 · DOI
- Choi, 2011, Liver Engraftment Potential of Hepatic Cells Derived from Patient-specific Induced Pluripotent Stem Cells, Cell Cycle, 10, 2423, 10.4161/cc.10.15.16869 · DOI
- Comeau, 2007, Cisapride Class-Action Suit Approved, Can. Med. Assoc. J., 176, 615, 10.1503/cmaj.070156 · doi:10.1503/cmaj.070156
- Craveiro, 2020, Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision, Cds, 15, 4, 10.2174/1574886314666191004092520 · DOI
- Crumb, 2016, An Evaluation of 30 Clinical Drugs against the Comprehensive In Vitro Proarrhythmia Assay (CiPA) Proposed Ion Channel Panel, J. Pharmacol. Toxicol. Methods, 81, 251, 10.1016/j.vascn.2016.03.009 · DOI · Paper page
- Dalgetty, 2009, Progress and Future Challenges in Stem Cell-Derived Liver Technologies, Am. J. Physiology-Gastrointestinal Liver Physiol., 297, G241, 10.1152/ajpgi.00138.2009 · DOI · Paper page
- Dash, 2009, Liver Tissue Engineering in the Evaluation of Drug Safety, Expert Opin. Drug Metab. Toxicol., 5, 1159, 10.1517/17425250903160664 · DOI · Paper page
- Dittrich, 2006, Lab-on-a-chip: Microfluidics in Drug Discovery, Nat. Rev. Drug Discov., 5, 210, 10.1038/nrd1985 · DOI · Paper page
- Dunn, 1991, Long-term In Vitro Function of Adult Hepatocytes in a Collagen Sandwich Configuration, Biotechnol. Prog., 7, 237, 10.1021/bp00009a007 · DOI · Paper page
- Ebrahimkhani, 2014, Bioreactor Technologies to Support Liver Function In Vitro, Adv. Drug Deliv. Rev., 132, 10.1016/j.addr.2014.02.011 · DOI · Paper page
- Ewer, 2015, Cardiotoxicity of Anticancer Treatments, Nat. Rev. Cardiol., 12, 547, 10.1038/nrcardio.2015.65 · DOI · Paper page
- Fridericia, 1920, Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken, Acta Med. Scand., 53, 469, 10.1111/j.0954-6820.1920.tb18266.x · DOI · Paper page
- Fridericia, 2003, The Duration of Systole in an Electrocardiogram in Normal Humans and in Patients with Heart Disease*, Ann. Noninvasive Electrocardiol., 8, 343, 10.1046/j.1542-474x.2003.08413.x · DOI · Paper page
- Gieseck, 2014, Maturation of Induced Pluripotent Stem Cell Derived Hepatocytes by 3D-Culture, PLoS ONE, 9, e86372, 10.1371/journal.pone.0086372 · DOI · Paper page
- Griffith, 2014, Engineering Liver, Hepatology, 60, 1426, 10.1002/hep.27150 · DOI · Paper page
- Guo, 2011, Estimating the Risk of Drug-Induced Proarrhythmia Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Toxicol. Sci., 123, 281, 10.1093/toxsci/kfr158 · DOI · Paper page
- Hannan, 2013, Production of Hepatocyte-like Cells from Human Pluripotent Stem Cells, Nat. Protoc., 8, 430, 10.1038/nprot.2012.153 · DOI · Paper page
- Haraguchi, 2015, Electrophysiological Analysis of Mammalian Cells Expressing hERG Using Automated 384-Well-Patch-Clamp, BMC Pharmacol. Toxicol., 16, 16, 10.1186/s40360-015-0042-9 · doi:10.1186/s40360-015-0042-9
- Harris, 2013, Comparison of Electrophysiological Data from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Functional Preclinical Safety Assays, Toxicol. Sci., 134, 412, 10.1093/toxsci/kft113 · DOI · Paper page
- Herper, 2013, The Cost of Creating a New Drug Now $5 Billion, Pushing Big Pharma to Change
- Hondeghem, 2001, Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic, Circulation, 103, 2004, 10.1161/01.cir.103.15.2004 · DOI · Paper page
- Hondeghem, 2008, Use and Abuse of QT and TRIaD in Cardiac Safety Research: Importance of Study Design and Conduct, Eur. J. Pharmacol., 584, 1, 10.1016/j.ejphar.2008.01.016 · DOI
- Horn, 1987, Alcoholic Liver Injury: Defenestration in Noncirrhotic Livers-A Scanning Electron Microscopic Study, Hepatology, 7, 77, 10.1002/hep.1840070117 · DOI · Paper page
- Huang, 2015, A Photostable Silicon Rhodamine Platform for Optical Voltage Sensing, J. Am. Chem. Soc., 137, 10767, 10.1021/jacs.5b06644 · DOI · Paper page
- Huebsch, 2018, Metabolically-Driven Maturation of hiPSC-Cell Derived Heart-On-A-Chip, bioRxiv, 485169, 10.1101/485169 · DOI
- Huebsch, 2015, Automated Video-Based Analysis of Contractility and Calcium Flux in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Cultured over Different Spatial Scales, Tissue Eng. C: Methods, 21, 467, 10.1089/ten.tec.2014.0283 · DOI · Paper page
- Hyland, 2003, Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole, Drug Metab. Dispos, 31, 540, 10.1124/dmd.31.5.540 · DOI · Paper page
- Inamdar, 2011, Microfluidic Cell Culture Models for Tissue Engineering, Curr. Opin. Biotechnol., 22, 681, 10.1016/j.copbio.2011.05.512 · DOI · Paper page
- Inamdar, 2011, Transport and Shear in a Microfluidic Membrane Bilayer Device for Cell Culture, Biomicrofluidics, 5, 022213, 10.1063/1.3576925 · DOI
- Jæger, 2019, Improved Computational Identification of Drug Response Using Optical Measurements of Human Stem Cell Derived Cardiomyocytes in Microphysiological Systems, Front. Pharmacol., 10, 1648, 10.3389/fphar.2019.01648 · DOI
- Jianling, 2009, Recent Advances in Physicochemical and ADMET Profiling in Drug Discovery, Chem. Biodiversity, 6, 1887, 10.1002/cbdv.200900117 · DOI
- Kim, 2013, Mathematical Analysis of Oxygen Transfer through Polydimethylsiloxane Membrane between Double Layers of Cell Culture Channel and Gas Chamber in Microfluidic Oxygenator, Microfluid Nanofluid, 15, 285, 10.1007/s10404-013-1142-8 · DOI · Paper page
- Kyungsuk, 2014, Physiologically Relevant Organs on Chips, Biotechnol. J., 9, 16, 10.1002/biot.201300187 · DOI · Paper page
- Laughner, 2012, Processing and Analysis of Cardiac Optical Mapping Data Obtained with Potentiometric Dyes, Am. J. Physiology-Heart Circulatory Physiol., 303, H753, 10.1152/ajpheart.00404.2012 · DOI · Paper page
- Lee, 2018, Gut-liver on a Chip toward an In Vitro Model of Hepatic Steatosis, Biotechnol. Bioeng., 115, 2817, 10.1002/bit.26793 · DOI · Paper page
- Lee-Montiel, 2017, Control of Oxygen Tension Recapitulates Zone-specific Functions in Human Liver Microphysiology Systems, Exp. Biol. Med. (Maywood), 242, 1617, 10.1177/1535370217703978 · DOI · Paper page
- Liang, 2013, Drug Screening Using a Library of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals Disease-specific Patterns of Cardiotoxicity, Circulation, 127, 1677, 10.1161/circulationaha.113.001883 · DOI · Paper page
- Liu, 2011, In Vivo Liver Regeneration Potential of Human Induced Pluripotent Stem Cells from Diverse Origins, Sci. Translational Med., 3, 82ra39, 10.1126/scitranslmed.3002376 · DOI · Paper page
- Liu, 2010, Generation of Endoderm-Derived Human Induced Pluripotent Stem Cells from Primary Hepatocytes, Hepatology, 51, 1810, 10.1002/hep.23626 · DOI · Paper page
- Liu, 2006, Blinded Validation of the Isolated Arterially Perfused Rabbit Ventricular Wedge in Preclinical Assessment of Drug-Induced Proarrhythmias, Heart Rhythm, 3, 948, 10.1016/j.hrthm.2006.04.021 · DOI
- Loskill, 2017, WAT-on-a-chip: a Physiologically Relevant Microfluidic System Incorporating White Adipose Tissue, Lab. Chip, 17, 1645, 10.1039/c6lc01590e · DOI · Paper page
- Marconi, 2014, Postnatal Hyperoxia Exposure Differentially Affects Hepatocytes and Liver Haemopoietic Cells in Newborn Rats, PLoS One, 9, e105005, 10.1371/journal.pone.0105005 · DOI
- Markov, 2014, Variation in Diffusion of Gases through PDMS Due to Plasma Surface Treatment and Storage Conditions, Biomed. Microdevices, 16, 91, 10.1007/s10544-013-9808-2 · DOI · Paper page
- Mathur, 2013, Human Induced Pluripotent Stem Cell-Based Microphysiological Tissue Models of Myocardium and Liver for Drug Development, Stem Cel Res. Ther., 4, S14, 10.1186/scrt375 · DOI · Paper page
- Mathur, 2015, Human iPSC-Based Cardiac Microphysiological System for Drug Screening Applications, Scientific Rep., 5, 8883, 10.1038/srep08883 · DOI · Paper page
- McAleer, 2019, On the Potential of In Vitro Organ-Chip Models to Define Temporal Pharmacokinetic-Pharmacodynamic Relationships, Sci. Rep., 9, 9619, 10.1038/s41598-019-45656-4 · DOI · Paper page
- Meuldermans, 1988, Excretion and Biotransformation of Cisapride in Dogs and Humans after Oral Administration, Drug Metab. Dispos, 16, 403
- Mi, 2013, Efficient Drug Screening and Gene Correction for Treating Liver Disease Using Patient‐specific Stem Cells, Hepatology, 57, 2458, 10.1002/hep.26237 · DOI · Paper page
- Michalets, 2000, Drug Interactions with Cisapride, Clin. Pharmacokinet., 39, 49, 10.2165/00003088-200039010-00004 · DOI
- Mishra, 2009, Real Time In Vitro Measurement of Oxygen Uptake Rates for HEPG2 Liver Cells Encapsulated in Alginate Matrices, Microfluid Nanofluid, 6, 373, 10.1007/s10404-008-0396-z · DOI
- Moradi, 2020, Microfluidic Organ-On-A-Chip Models of Human Liver Tissue, Acta Biomater., 116, 67, 10.1016/j.actbio.2020.08.041 · DOI · Paper page
- Mun, 2019, Generation of Expandable Human Pluripotent Stem Cell-Derived Hepatocyte-like Liver Organoids, J. Hepatol., 71, 970, 10.1016/j.jhep.2019.06.030 · DOI · Paper page
- Nahmias, 2006, Endothelium-Mediated Hepatocyte Recruitment in the Establishment of Liver-like TissueIn Vitro, Tissue Eng., 12, 1627, 10.1089/ten.2006.12.1627 · DOI · Paper page
- Okada, 2015, Screening System for Drug-Induced Arrhythmogenic Risk Combining a Patch Clamp and Heart Simulator, Sci. Adv., 1, 2375, 10.1126/sciadv.1400142 · DOI · Paper page
- Oleaga, 2018, Investigation of the Effect of Hepatic Metabolism on Off-Target Cardiotoxicity in a Multi-Organ Human-On-A-Chip System, Biomaterials, 182, 176, 10.1016/j.biomaterials.2018.07.062 · DOI · Paper page
- Paakkari, 2002, Cardiotoxicity of New Antihistamines and Cisapride, Toxicol. Lett., 127, 279, 10.1016/s0378-4274(01)00510-0 · DOI
- Park, 2005, Microfabricated Grooved Substrates as Platforms for Bioartificial Liver Reactors, Biotechnol. Bioeng., 90, 632, 10.1002/bit.20463 · DOI · Paper page
- Park, 2008, Radial Flow Hepatocyte Bioreactor Using Stacked Microfabricated Grooved Substrates, Biotechnol. Bioeng., 99, 455, 10.1002/bit.21572 · DOI · Paper page
- Pearce, 2001, Cytochrome P450 Involvement in the Biotransformation of Cisapride and Racemic Norcisapride In Vitro: Differential Activity of Individual Human CYP3A Isoforms, Drug Metab. Dispos, 29, 1548
- Pires de Mello, 2020, Microphysiological Heart-Liver Body-On-A-Chip System with a Skin Mimic for Evaluating Topical Drug Delivery, Lab. Chip, 20, 749, 10.1039/c9lc00861f · DOI
- Provin, 2009, Low O2 Metabolism of HepG2 Cells Cultured at High Density in a 3D Microstructured Scaffold, Biomed. Microdevices, 11, 485, 10.1007/s10544-008-9254-8 · DOI
- Redfern, 2003, Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development, Cardiovasc. Res., 58, 32, 10.1016/s0008-6363(02)00846-5 · DOI · Paper page
- Schepers, 2016, Engineering a Perfusable 3D Human Liver Platform from iPS Cells, Lab. Chip, 16, 2644, 10.1039/c6lc00598e · DOI · Paper page
- Scott, 2013, Human Induced Pluripotent Stem Cells and Their Use in Drug Discovery for Toxicity Testing, Toxicol. Lett., 219, 49, 10.1016/j.toxlet.2013.02.020 · DOI
- Shah, 2002, The Significance of QT Interval in Drug Development, Br. J. Clin. Pharmacol., 54, 188, 10.1046/j.1365-2125.2002.01627.x · DOI · Paper page
- Shimada, 1996, Characterization of Microsomal Cytochrome P450 Enzymes Involved in the Oxidation of Xenobiotic Chemicals in Human Fetal Liver and Adult Lungs, Drug Metab. Dispos, 24, 515
- Shirure, 2017, Design Considerations to Minimize the Impact of Drug Absorption in Polymer-Based Organ-On-A-Chip Platforms, Lab. Chip, 17, 681, 10.1039/c6lc01401a · DOI · Paper page
- Sip, 2014, Stable Chemical Bonding of Porous Membranes and Poly (Dimethylsiloxane) Devices for Long-Term Cell Culture, Biomicrofluidics, 8, 036504, 10.1063/1.4883075 · DOI
- Soldatow, 2013, In vitro models for Liver Toxicity Testing, Toxicol. Res., 2, 23, 10.1039/c2tx20051a · DOI · Paper page
- Song, 2009, Efficient Generation of Hepatocyte-like Cells from Human Induced Pluripotent Stem Cells, Cell Res, 19, 1233, 10.1038/cr.2009.107 · DOI · Paper page
- Sung, 2010, In vitro microscale Systems for Systematic Drug Toxicity Study, Bioproc. Biosyst Eng, 33, 5, 10.1007/s00449-009-0369-y · DOI
- Takahashi, 2007, Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors, Cell, 131, 10.1016/j.cell.2007.11.019 · DOI · Paper page
- Takahashi, 2006, Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors, Cell, 126, 663, 10.1016/j.cell.2006.07.024 · DOI · Paper page
- Tilles, 2001, Effects of Oxygenation and Flow on the Viability and Function of Rat Hepatocytes Cocultured in a Microchannel Flat-Plate Bioreactor, Biotechnol. Bioeng., 73, 379, 10.1002/bit.1071 · DOI · Paper page
- Tréluyer, 2001, Evidence of Impaired Cisapride Metabolism in Neonates, Br. J. Clin. Pharmacol., 52, 419, 10.1046/j.0306-5251.2001.01470.x · DOI
- Tuschl, 2009, Serum-free Collagen Sandwich Cultures of Adult Rat Hepatocytes Maintain Liver-like Properties Long Term: A Valuable Model for In Vitro Toxicity and Drug-Drug Interaction Studies, Chemico-Biological Interactions, 181, 124, 10.1016/j.cbi.2009.05.015 · DOI
- Tveito, 2018, Inversion and Computational Maturation of Drug Response Using Human Stem Cell Derived Cardiomyocytes in Microphysiological Systems, Sci. Rep., 8, 17626, 10.1038/s41598-018-35858-7 · DOI
- Vinci, 2011, Modular Bioreactor for Primary Human Hepatocyte Culture: Medium Flow Stimulates Expression and Activity of Detoxification Genes, Biotechnol. J., 6, 554, 10.1002/biot.201000326 · DOI · Paper page
- Vollmar, 2009, The Hepatic Microcirculation: Mechanistic Contributions and Therapeutic Targets in Liver Injury and Repair, Physiol. Rev., 89, 1269, 10.1152/physrev.00027.2008 · DOI · Paper page
- Wiseman, 1994, Cisapride, Drugs, 47, 116, 10.2165/00003495-199447010-00008 · DOI · Paper page
- Wysowski, 1996, Cisapride and Fatal Arrhythmia, N. Engl. J. Med., 335, 290, 10.1056/nejm199607253350416 · DOI · Paper page
- Wysowski, 2001, Postmarketing Reports of QT Prolongation and Ventricular Arrhythmia in Association with Cisapride and Food and Drug Administration Regulatory Actions, Am. J. Gastroenterol., 96, 1698, 10.1111/j.1572-0241.2001.03927.x · doi:10.1111/j.1572-0241.2001.03927.x · Paper page
- Zhu, 2014, Mouse Liver Repopulation with Hepatocytes Generated from Human Fibroblasts, Nature, 508, 93, 10.1038/nature13020 · DOI · Paper page
Cited by
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
Organ-on-a-chip meets artificial intelligence in drug evaluation
Deng, S., Li, C., Cao, J., Cui, Z., Du, J., Fu, Z., Yang, H., & Chen, P. (2023) · Theranostics · doi:10.7150/thno.87266 · Cited by 260
Liver–heart on chip models for drug safety
Ferrari, E., & Rasponi, M. (2021) · APL Bioengineering · doi:10.1063/5.0048986 · Cited by 53
Dufva, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-35043-5 · Cited by 14
Metadata
- Authors
- Lee-Montiel, F. T., Laemmle, A., Charwat, V., Dumont, L., Lee, C. S., Huebsch, N., Okochi, H., Hancock, M. J., Siemons, B., Boggess, S. C., Goswami, I., Miller, E. W., Willenbring, H., & Healy, K. E.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-05-07
- Volume
- 12
- Pages
- 667010-667010
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3157067478
- Cited by
- 54
- References
- 25
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrated Isogenic Human Induced Pluripotent Stem Cell–Based Liver and Heart Microphysiological Systems Predict Unsafe Drug–Drug Interaction. https://app.cochat.ai/papers/10.3389/fphar.2021.667010
- The paper
- Lee-Montiel, F. T., Laemmle, A., Charwat, V., Dumont, L., Lee, C. S., Huebsch, N., Okochi, H., Hancock, M. J., Siemons, B., Boggess, S. C., Goswami, I., Miller, E. W., Willenbring, H., & Healy, K. E. (2021). Integrated Isogenic Human Induced Pluripotent Stem Cell–Based Liver and Heart Microphysiological Systems Predict Unsafe Drug–Drug Interaction. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.667010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.